laromustine
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT00521859 | Aug 2007 → Dec 2010 | hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00516282 | Aug 2007 → Oct 2009 | central nervous system neoplasm | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT00098761 | Feb 2005 → Oct 2006 | central nervous system neoplasm | Pediatric Brain Tumor Consortium | Completed | No outcome recorded |
| Phase 1 | NCT00098436 | Sep 2004 → Oct 2006 | leukemia | Vion Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00070538 | Jun 2003 → Sep 2004 | leukemia, myelodysplastic syndrome | Vion Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00049699 | Oct 2002 → Jan 2008 | lymphoma, small intestine cancer | Vion Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00049686 | Apr 2002 → Jan 2008 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease | Vion Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00025129 | Mar 2001 → May 2004 | lymphoma, small intestine cancer | Vion Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT00840684 | Jan 2009 → May 2011 | leukemia | Institut Paoli-Calmettes | Completed | No outcome recorded |
| Phase 1/2 | NCT00655395 | Mar 2008 → Apr 2010 | acute myeloid leukemia, myelodysplastic syndrome | Viron Therapeutics Inc | Terminated | No outcome recorded |
| Phase 1/2 | NCT00304005 | Jul → Oct 2005 | leukemia, lymphoma | Vion Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00354276 | May 2006 → Dec 2008 | leukemia | Vion Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT00083187 | Nov 2005 → Jan 2007 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | Vion Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00282022 | Sep 2005 → May 2008 | small cell lung carcinoma | Vion Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00112554 | Mar 2005 → Mar 2008 | leukemia | Vion Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-06 | Neuren Pharmaceuticals Limited | Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025 neurenpharma.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | laromustine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00049699 ↗ |
| Known as | 101M | ChEMBL registry synonym — accepted as the source's own label CHEMBL167691 ↗ |
| Known as | Cloretazine | “Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.” PMID 16278404 ↗ Nov 20054“A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia” NCT00354276 ↗ “A Phase II Trial of Cloretazine™ (VNP40101M) for Patients With Relapsed or Refractory Small Cell Lung Cancer” NCT00282022 ↗ |
| Known as | Laromustin | ChEMBL registry synonym — accepted as the source's own label CHEMBL167691 ↗ |
| Known as | Laromustina | ChEMBL registry synonym — accepted as the source's own label CHEMBL167691 ↗ |
| Known as | NSC-734246 | ChEMBL registry synonym — accepted as the source's own label CHEMBL167691 ↗ |
| Known as | Onrigin | ChEMBL registry synonym — accepted as the source's own label CHEMBL167691 ↗ |
| Known as | VNP40101M | “Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid...” PMID 19710500 ↗ Aug 20096“Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.” PMID 16278404 ↗ Nov 2005 “A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia” NCT00354276 ↗ “A Phase II Trial of Cloretazine™ (VNP40101M) for Patients With Relapsed or Refractory Small Cell Lung Cancer” NCT00282022 ↗ “Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.” PMID 20511167 ↗ Jun 2010 “A Phase I Trial Of VNP40101M, A Novel Alkylating Agent, For Patients With Hematologic Malignancies” NCT00049686 ↗ “Laromustine (VNP40101M), A Sulfonylhydrazine Alkylating Agent” NCT00655395 ↗ |
| Modality | Other / unclassified | “a novel sulfonylhydrazine alkylating agent” PMID 16278404 ↗ Nov 2005 |
| Route | Intravenous | “Patients receive VNP40101M IV over 15 minutes” NCT00025129 ↗ |